177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine-Reference-Cited by-同舟云学术

177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine

Published:2021-06-24 Issue:8 Volume:62 Page:1025-1026
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Czernin Johannes,Calais Jeremie

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference13 articles.

1. 3 study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION) [abstract;Morris;J Clin Oncol,2021

2. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients;Horoszewicz;Anticancer Res.,1987

3. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen;Israeli;Cancer Res.,1993

4. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice

5. ¹¹C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase)

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer;EJNMMI Radiopharmacy and Chemistry;2024-08-24

2. Lutetium-177 radioisotope and therapeutic radiopharmaceuticals: Production, separation and purification, chelation labeling and clinical application;Chinese Science Bulletin;2024-04-12

3. Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals;Applied Radiation and Isotopes;2023-07

4. SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer—Use of Imaging Agents in Therapeutic Drug Development and Approval;Journal of Nuclear Medicine Technology;2022-06-14

5. Lutetium Lu 177 Vipivotide Tetraxetan: First Approval;Molecular Diagnosis & Therapy;2022-05-13